⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
SAGILITY - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 2.9
| Stock Code | SAGILITY | Market Cap | 22,695 Cr. | Current Price | 48.4 ₹ | High / Low | 57.9 ₹ |
| Stock P/E | 59.3 | Book Value | 22.1 ₹ | Dividend Yield | 0.10 % | ROCE | 4.37 % |
| ROE | 2.88 % | Face Value | 10.0 ₹ | DMA 50 | 50.7 ₹ | DMA 200 | 46.7 ₹ |
| Chg in FII Hold | 4.66 % | Chg in DII Hold | 6.49 % | PAT Qtr | 93.4 Cr. | PAT Prev Qtr | 111 Cr. |
| RSI | 37.9 | MACD | -0.32 | Volume | 1,96,58,797 | Avg Vol 1Wk | 5,66,37,722 |
| Low price | 37.6 ₹ | High price | 57.9 ₹ | PEG Ratio | 0.20 | Debt to equity | 0.09 |
| 52w Index | 53.4 % | Qtr Profit Var | -15.2 % | EPS | 0.77 ₹ | Industry PE | 25.7 |
📊 Core Financials
- Quarterly PAT declined to 93.4 Cr from 111 Cr (-15.2%), showing weak earnings momentum.
- ROE at 2.88% and ROCE at 4.37% are very low, reflecting poor capital efficiency.
- Debt-to-equity ratio at 0.09 indicates a nearly debt-free balance sheet.
- Cash flows remain modest, with profitability under pressure.
💹 Valuation Indicators
- P/E ratio: 59.3, significantly higher than industry average of 25.7, suggesting overvaluation.
- P/B ratio: ~2.19 (48.4 ₹ / 22.1 ₹ book value), moderate premium.
- PEG ratio: 0.20, indicating valuation is expensive relative to growth.
- Intrinsic value appears lower than current price, limited margin of safety.
🏢 Business Model & Competitive Advantage
- Sagility operates in IT-enabled services and outsourcing, focusing on healthcare and business process management.
- Competitive advantage lies in niche specialization and global delivery capabilities.
- However, profitability metrics remain weak compared to peers, limiting overall strength.
📈 Entry Zone & Long-Term Guidance
- Entry zone: 42–46 ₹ range (near 200 DMA support at 46.7 ₹).
- Long-term holding only recommended for high-risk investors seeking exposure to niche outsourcing.
- Better to wait for earnings improvement before accumulating heavily.
Positive
- Debt-to-equity ratio at 0.09, nearly debt-free.
- Strong institutional interest with FII (+4.66%) and DII (+6.49%) increases.
- Specialization in healthcare outsourcing provides niche positioning.
Limitation
- Low ROE (2.88%) and ROCE (4.37%).
- High P/E (59.3) compared to industry average (25.7).
- Dividend yield at 0.10% is negligible.
Company Negative News
- Quarterly PAT declined (-15.2%), raising concerns on earnings stability.
- Weak technical indicators (RSI at 37.9, MACD negative).
Company Positive News
- Institutional holdings increased significantly, showing confidence from FII and DII investors.
- Stock trading above 200 DMA (46.7 ₹), providing technical support.
Industry
- Industry PE at 25.7, much lower than Sagility’s 59.3, highlighting sector undervaluation relative to Sagility.
- IT-enabled services and healthcare outsourcing expected to grow steadily with global demand.
Conclusion
- Sagility is fundamentally weak with low profitability and stretched valuations.
- Debt-free status and institutional support provide some stability.
- Accumulation only near 42–46 ₹ for long-term investors willing to take higher risk in niche outsourcing.
Would you like me to also contrast Sagility’s fundamentals with peers like Coforge or Firstsource to highlight relative strengths and weaknesses?